Avaleht › Eesnäärmevähk › Ohio › Columbus
Eesnäärmevähk kliinilised uuringud linnas Columbus, OH
24 uuringut haiguse Eesnäärmevähk jaoks otsivad osalejaid linnas Columbus ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
VärbamineFaas 3
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- ja veel 8
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
VärbamineFaas 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
VärbamineFaas 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- ja veel 11
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
VärbamineFaas 2/3
- Central Ohio Urology Group, Gahanna · 7 mi kaugusel
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
VärbamineFaas 3
- The Ohio State University, Columbus
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
VärbamineFaas 3
- Central Ohio Urology Group, Gahanna · 7 mi kaugusel
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
VärbamineFaas 3
- Research Site, Columbus
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
VärbamineFaas 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
VärbamineFaas 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- ja veel 4
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
VärbamineFaas 1/2
- The Ohio State University, Columbus
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
VärbamineFaas 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
VärbamineFaas 1
- The Ohio State University, Columbus
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
VärbamineFaas 1
- The Ohio State University, Columbus
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
VärbamineFaas 3
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
VärbamineFaas 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
VärbamineFaas 1
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
VärbamineFaas 1
- Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
VärbamineFaas 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
VärbamineFaas 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
VärbamineFaas 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
VärbamineVaatlusuuring
- Massive Bio SYNERGY-AI site, Columbus
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
VärbamineFaas 3
- Ohio State University Comprehensive Cancer Center, Columbus
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
VärbamineFaas 2
- Central Ohio Urology Group, Gahanna · 7 mi kaugusel
Eesnäärmevähk uuringud teistes linnades
- New York City, NY103 uuringut
- Houston, TX76 uuringut
- Los Angeles, CA61 uuringut
- Boston, MA59 uuringut
- St. Louis, MO46 uuringut
- Chicago, IL45 uuringut
- San Francisco, CA45 uuringut
- Philadelphia, PA44 uuringut
- Baltimore, MD43 uuringut
- Nashville, TN42 uuringut
- Seattle, WA42 uuringut
- Washington, DC38 uuringut
Muud uuringud linnas Columbus
- Mitteväikerakuline kopsuvähk56 uuringut
- Rinnavähk39 uuringut
- Munasarjavähk39 uuringut
- Vähk (kõik liigid)38 uuringut
- Kopsuvähk37 uuringut
- Äge müeloidne leukeemia35 uuringut
- Krooniline lümfotsütaarne leukeemia28 uuringut
- Metastaatiline vähk27 uuringut
- Endomeetriumivähk25 uuringut
- Käär- ja pärasoolevähk24 uuringut
- Müeloom24 uuringut
- Melanoom21 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.